Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Michael G. Hanna Jr.
Vaccinogen,USA
Michael G. Hanna, Jr., Ph.D., a pioneer in cancer immunotherapy, co-founded Vaccinogen in 2007 and served as Chairman and CEO. Currently, Dr. Hanna is Chairman Emeritus of the Company’s Board of Directors.Dr. Hanna is the discoverer and developer of Vaccinogen’s lead product, OncoVAX, an autologous vaccine designed to elicit a specifc immune response against minimal residual disease after surgery. Vaccinogen believes OncoVAX is the first product to show a significant reduction in recurrence of disease in stage II colon cancer patients.
Oncology, Immunology, Human Vaccines, Immunotherapeutics, experimental pathology